Get the Stockscreener App
1.43
3.62%
0.05
After Hours:
1.59
0.16
+11.19%
Anebulo Pharmaceuticals Inc stock is traded at $1.43, with a volume of 88,374.
It is up +3.62% in the last 24 hours and up +7.52% over the past month.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
See More
Previous Close:
$1.38
Open:
$1.3301
24h Volume:
88,374
Relative Volume:
2.54
Market Cap:
$58.75M
Revenue:
-
Net Income/Loss:
$-7.92M
P/E Ratio:
-4.7667
EPS:
-0.3
Net Cash Flow:
$-7.05M
1W Performance:
+40.20%
1M Performance:
+7.52%
6M Performance:
-31.25%
1Y Performance:
-40.91%
1-Day Range:
$1.3301
$1.68
1-Week Range:
$0.9078
$1.70
52-Week Range:
$0.8001
$3.30
Anebulo Pharmaceuticals Inc Stock (ANEB) Company Profile
Name
Anebulo Pharmaceuticals Inc
Sector
Industry
Phone
737 203 5270
Address
JFL CAPITAL MANAGEMENT, LAKEWAY
Compare ANEB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANEB
Anebulo Pharmaceuticals Inc
|
1.43 | 58.75M | 0 | -7.92M | -7.05M | -0.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Anebulo Pharmaceuticals Inc Stock (ANEB) Latest News
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Anebulo Pharmaceuticals Inc Files For Resale Of Up To 15.15 Million Shares By The Selling Stockholders - Marketscreener.com
Benchmark maintains Speculative Buy on Anebulo stock, target at $8 By Investing.com - Investing.com Canada
Anebulo Pharmaceuticals enters lock-up agreement, faces Nasdaq compliance issue By Investing.com - Investing.com South Africa
Anebulo Pharmaceuticals enters lock-up agreement, faces Nasdaq compliance issue - Investing.com
Anebulo Pharmaceuticals files to sell 15.15M shares of common stock for holders - MSN
Anebulo Pharmaceuticals Reports Fiscal Q2 2025 Results - TipRanks
Anebulo Pharmaceuticals Inc Files Prospectus Related To Resale Of 15.2 Million Shares Of Common Stock By Selling Stockholders- SEC Filing - Marketscreener.com
Anebulo Pharmaceuticals Inc. (ANEB) reports earnings - Quartz
Anebulo Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Anebulo Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Anebulo's Cannabis Overdose Treatment Gets FDA Priority Signal as Company Raises $15M - StockTitan
Head to Head Contrast: ProQR Therapeutics (NASDAQ:PRQR) versus Anebulo Pharmaceuticals (NASDAQ:ANEB) - Defense World
Anebulo Pharmaceuticals sets annual meeting for April 4, 2025 By Investing.com - Investing.com Nigeria
Anebulo Pharmaceuticals sets annual meeting for April 4, 2025 - MSN
Anebulo Pharmaceuticals Leads This Trio Of US Penny Stocks - Yahoo Finance
Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Increases By 2,174.1% - Defense World
Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Expands By 2,174.1% - Defense World
3 US Penny Stocks With Market Caps Under $800M - Yahoo Finance
Anebulo Pharmaceuticals sees $9.99m stock acquisition by 22NW fund - Investing.com Australia
Anebulo Pharmaceuticals collaborates with FDA to advance selonabant - Yahoo Finance
Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise - BioSpace
Anebulo Pharmaceuticals secures $15 million capital raise - Investing.com
Anebulo Reports Breakthrough Clinical Data for Cannabis Toxicity Treatment, Secures $15M Funding - StockTitan
Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock Price Down 9.8% – Should You Sell? - Defense World
Anebulo Pharmaceuticals stock hits 52-week low at $1.23 - Investing.com India
Anebulo Pharmaceuticals stock hits 52-week low at $1.23 By Investing.com - Investing.com South Africa
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com
Anebulo Pharmaceuticals stock hits 52-week low at $1.25 By Investing.com - Investing.com Australia
Anebulo Pharmaceuticals stock hits 52-week low at $1.25 - Investing.com India
Anebulo Pharmaceuticals Advances Cannabis Toxicity Solutions - MSN
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates - Defense World
Anebulo Pharma Secures $1.9M NIDA Grant for Cannabis Toxicity Treatment Development | ANEB Stock News - StockTitan
Anebulo Pharmaceuticals stock hits 52-week low at $1.72 - Investing.com
Anebulo Pharmaceuticals stock hits 52-week low at $1.72 By Investing.com - Investing.com UK
Exxaro Resources (OTCMKTS:EXXAY) Share Price Crosses Above 200 Day Moving Average – What’s Next? - Defense World
Lexeo Therapeutics’ (LXEO) “Buy” Rating Reiterated at Chardan Capital - Defense World
Short Interest in Janone Inc. (NASDAQ:ALTS) Expands By 10.2% - Defense World
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.21% - MSN
Anebulo Pharmaceuticals Inc Stock (ANEB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):